P-12 peptide

P-12 peptide is a **de novo designed, chemically synthesized peptide** that functions as a selective **antagonist of the C-X-C chemokine receptor type 4 (CXCR4)**. It was developed via pancreatic-cancer-cell-based selection and characterized for its ability to bind specifically to **CXCR4-positive pancreatic cancer cells**, as well as fibroblasts and macrophages. The peptide inhibits the **CXCL12/CXCR4 signaling axis**, reducing phosphorylation of Erk and p38 kinases, thereby inhibiting tumor cell migration and stromal interactions. P-12 enhances sensitivity of pancreatic tumor cells to **gemcitabine** (a standard chemotherapeutic agent) and, in combination with gemcitabine, significantly prolongs survival and reduces tumor burden in mouse models of pancreatic cancer. It also remodels the tumor microenvironment by increasing infiltration and killing activity of CD8+ T lymphocytes and decreasing fibroblast abundance. In vivo, P-12 demonstrates selective pancreatic cancer tissue accumulation and is rapidly eliminated from liver and kidney. Mechanistically, it exerts **immunomodulatory and chemosensitizing effects** that disrupt tumor immune evasion and chemoresistance[3]. No approved commercial brand or product is known at this time, and current data are preclinical.

Other names

P12P-12P 12